Archive for the 'Trimodality Therapy' Category
Preoperative chemotherapy and postoperative radiation.
December 23rd, 2008. Malignant mesothelioma
Compensation issues must also be considered. Life expectancy in malignant mesothelioma is poor, with a median survival of about one year following diagnosis.
Posted in Benign, CT or CAT scan, Causation, Diagnosis & Differentiation, Environmental Asbestos Exposure, Full Archive, General, Occupational Asbestos Exposure, Pericardial, Peritoneal (Abdominal Mesothelioma), Pleural, Survival, Symptoms & Symptom Management, Treatment, Trimodality Therapy, Tunica Vaginalis Testis, Type of Assessment:, Type of Mesothelioma: | No Comments »
October 9th, 2008. Peritoneal Mesothelioma
To date there have been no universally accepted treatments for MPM. Unless referred to a specialty center, patients are routinely treated with pemetrexed and cisplatin which has been shown to increase survival in pleural mesothelioma.
Posted in Chemotherapy, Cisplatin (Platinol ®), Determining Efficacy, Doxorubicin, Full Archive, Intraperitoneal Chemotherapy, Pemetrexed (Alimta), Peritoneal (Abdominal Mesothelioma), Surgery, Treatment, Trimodality Therapy, Tumor Debulking, Type of Assessment:, Type of Mesothelioma:, mitomycin-C | 1 Comment »
September 2nd, 2008. Diagnosis, Staging, and Surgical Treatment of Malignant Pleural Mesothelioma
The primary goal of surgery in this setting is the resection of all gross disease. The choice of operation, extrapleural pneumonectomy (EPP) or pleurectomy/decortication (P/D), depends on disease stage, pulmonary function, philosophy of the treating physician, and type of planned adjuvant therapy.
Posted in Chemotherapy, Determining Efficacy, Diagnosis & Differentiation, Extrapleural Pneumonectomy (EPP), Full Archive, Pleural, Pleurectomy/decortication, Staging, Surgery, Treatment, Trimodality Therapy, Tumor Debulking, Type of Assessment:, Type of Mesothelioma: | No Comments »
July 29th, 2008. Open lung-sparing surgery for malignant pleural mesothelioma: the benefits of a radical approach within multimodality therapy
Conclusion: If a patient with epithelioid MPM is fit enough to tolerate a thoracotomy then macroscopic clearance of the tumour is the preferred option as part of a multimodality regime including chemotherapy.
Posted in Chemotherapy, Epithelioid, Full Archive, Pleurectomy/decortication, Radiation, Surgery, Survival, Treatment, Trimodality Therapy, Type of Assessment:, Type of Mesothelioma: | No Comments »
July 9th, 2008. Malignant mesothelioma: current status and perspective in Japan and the world
In this context, combination therapy with surgery plus chemotherapy and/or radiotherapy is currently considered the standard treatment for patients with respectable MPM. A national survey of EPP was conducted recently in Japan, and a few multicenter clinical trials will start soon.
Posted in Chemotherapy, Diagnosis & Differentiation, Extrapleural Pneumonectomy (EPP), Full Archive, Pleural, Pleurectomy/decortication, Radiation, Staging, Surgery, Treatment, Trimodality Therapy, Type of Assessment:, Type of Mesothelioma:, thoracoscopy | No Comments »
June 24th, 2008. Multimodal Therapy for Malignant Pleural Mesothelioma Including Extrapleural Pneumonectomy
During the follow-up duration of 23 months, 3 patients (18 %) developed distant metastasis and one (6 %) a mediastinal local recurrence. Multimodal therapy of malignant pleural mesothelioma including extrapleural pneumonectomy should only be performed in specialised centres for thoracic surgery where uncomplicated interdisciplinary communication is the rule and which provide the required expertise in patient selection, operative technique and postoperative care.
Posted in Chemotherapy, Cisplatin (Platinol ®), Determining Efficacy, Extrapleural Pneumonectomy (EPP), Full Archive, Pemetrexed (Alimta), Radiation, Surgery, Survival, Treatment, Trimodality Therapy, Type of Assessment: | No Comments »
May 2nd, 2008. Trimodality Treatment of Malignant Pleural Mesothelioma
Conclusions: Trimodality treatment in malignant pleural mesothelioma seems to prolong survival in patients without lymph node metastasis. Novel techniques are needed for preoperative assessment of extrapleural lymph nodes.
Posted in Determining Efficacy, Epithelioid, Extrapleural Pneumonectomy (EPP), Full Archive, Sarcomatoid, Surgery, Survival, Treatment, Trimodality Therapy, Type of Assessment:, Type of Mesothelioma: | No Comments »
April 25th, 2008. Individual versus standard quality of life assessment in a phase II clinical trial in mesothelioma patients: Feasibility and responsiveness to clinical changes
Conclusion: The SEIQoL assessment seems to be feasible within a phase II clinical trial, but may require more effort from staff. More distinctive QoL changes in accordance with clinical changes were measured with the RSCL. Our findings suggest that the two measures are not interchangeable: the RSCL is to favor when mainly information related to the course of disease- and treatment is of interest.
Posted in Chemotherapy, Determining Efficacy, Full Archive, Pleural, Pneumonectomy, Radiation, Surgery, Survival, Treatment, Trimodality Therapy, Type of Assessment:, Type of Mesothelioma: | No Comments »
April 15th, 2008. Outcome after extrapleural pneumonectomy for malignant pleural mesothelioma
Conclusion: Extrapleural pneumonectomy as part of a multi-modality treatment regimen is a good treatment option for selected patients with malignant pleural mesothelioma. The long-term results of this limited series compare favourably to non-surgical treatment regimens. Larger randomised prospective multi-centre trials are warranted to establish clear guidelines.
April 1st, 2008. Combined resection, intraperitoneal chemotherapy, and whole abdominal radiation for the treatment of malignant peritoneal mesothelioma
Conclusion: Based on the results of this study, intensive multimodality therapy appears feasible and effective in this group of patients.
Posted in Chemotherapy, Cisplatin (Platinol ®), Determining Efficacy, Doxorubicin, Full Archive, Intraperitoneal Chemotherapy, Radiation, Surgery, Survival, Treatment, Trimodality Therapy, Tumor Debulking, Type of Assessment: | No Comments »
March 25th, 2008. Bcl-xL antisense oligonucleotide and cisplatin combination therapy extends survival in SCID mice with established mesothelioma xenografts
ASO 15999 induced reduction of Bcl-xL is effective in slowing the progression of human mesothelioma cell lines both in vitro and in vivo. More notably, the combination of Bcl-xL ASO and cisplatin extends survival in an orthotopic tumor xenograft model.
March 11th, 2008. Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: Results in 663 patients
Conclusion: Patients who underwent pleurectomy/decortication had a better survival than those who underwent extrapleural pneumonectomy; however, the reasons are multifactorial and subject to selection bias. At present, the choice of resection should be tailored to the extent of disease, patient comorbidities, and type of multimodality therapy planned.
February 26th, 2008. Malignant peritoneal mesothelioma tumours. Evolution, treatment, prognosis
The diagnosis of peritoneal mesothelioma is often delayed, in part because of the usually long latent period (peaking at 40-45 years from the time of initial exposure to asbestos) and because the common presenting symptoms of weight loss, usually with a full abdomen, malaise, and abdominal discomfort, are mild and nonspecific. This paper aim is to present a case report regarding a patient diagnosed with malignant peritoneal mesothelioma with an unpredictable evolution.
February 19th, 2008. Malignant pleural mesothelioma: multidisciplinary experience in a public tertiary hospital
Conclusions: In the cases studied, an integrated multidisciplinary approach was used, and a highly complex hospital infrastructure was available for the diagnosis and treatment of MPM, as recommended in the literature. However, the mean survival was only 11 months, reflecting the aggressiveness of the disease.
Posted in Biphasic or Mixed, Chemotherapy, Diagnosis & Differentiation, Epithelioid, Full Archive, General, Pleural, Pleural Biopsy, Pneumonectomy, Radiation, Sarcomatoid, Surgery, Treatment, Trimodality Therapy, Type of Assessment:, Type of Mesothelioma:, thoracoscopy | No Comments »
February 19th, 2008. Current concepts in malignant pleural mesothelioma
Treatment options for MPM remain limited and no consensus exists at this time. Multimodality therapy that combines surgery, chemotherapy and radiation offers the best chance for long-term survival in select patients.
January 12th, 2008. Helical Tomotherapy : Experiences of the First 150 Patients in Heidelberg
Conclusion: Helical tomotherapy and daily image guidance with MV-CT could fast
January 2nd, 2008. Malignant pleural mesothelioma: interrogations and hopes concerning the expected epidemic
In 2007, a more aggressive therapeutic approach is becoming common practice with the use of radiotherapy and the emergence of the concept of multimodal care centered on wide pleuropneumonectomy. These advances create real hope for improvement, but also many interrogations since no standard treatment protocol has been clearly identified.
Posted in Epidemiological, Extrapleural Pneumonectomy (EPP), Full Archive, General, Pleural, Pneumonectomy, Surgery, Treatment, Trimodality Therapy, Type of Assessment:, Type of Mesothelioma: | No Comments »
January 1st, 2008. Malignant pleural mesothelioma: clinicopathologic and survival characteristics in a consecutive series of 394 patients
Conclusions: Significant predictors of survival include performance status, platelet count, histology, and degree of involvement of pleural cavity. Within the confines of this retrospective study and the small number of patients undergoing multimodality therapy, the role of surgery in the treatment of MPM remains unclear. Further investigation is warranted to determine the optimal treatment strategy in this disease.
December 7th, 2007. Renal cell carcinoma with malignant pleural mesothelioma after asbestos exposure: a case report
The incidence is rising in industrialized countries, with the peak expected in the year 2020. However, renal cell carcinoma with malignant pleural mesothelioma is very rare and this is the 2nd case in the Japanese literature.
Posted in CT or CAT scan, Case Study, Causation, Chemotherapy, Diagnosis & Differentiation, Epidemiological, Extrapleural Pneumonectomy (EPP), Full Archive, Occupational Asbestos Exposure, Pleural, Pleural Effusion, Radiation, Surgery, Symptoms & Symptom Management, Treatment, Trimodality Therapy, Type of Assessment:, Type of Mesothelioma: | No Comments »
November 3rd, 2007. Clinical value of using serological cytokeratins as therapeutic markers in thoracic malignancies
Several studies have been initiated in which surrogate markers are evaluated in comparison to chest X-rays and computer tomography. The present review focuses on the predictive and prognostic value of using serological cytokeratins as tumour markers for patients suffering from thoracic malignancies.
|
|  |
